Literature DB >> 7513307

Formaldehyde treatment of proteins can constrain presentation to T cells by limiting antigen processing.

A di Tommaso1, M T de Magistris, M Bugnoli, I Marsili, R Rappuoli, S Abrignani.   

Abstract

Proteins to be used as vaccines are frequently treated with formaldehyde, although little is known about the effects of this treatment on protein antigenicity. To investigate the effect of formaldehyde treatment on antigen recognition by T cells, we compared the in vitro T-cell response to proteins that have been formaldehyde treated with the response to untreated proteins. We found that peripheral blood mononuclear cells from individuals vaccinated with three formaldehyde-treated proteins (pertussis toxin, filamentous hemagglutinin, pertactin) of Bordetella pertussis showed little or no response to the formaldehyde-treated proteins but proliferated very well in response to the corresponding untreated protein. These findings were further confirmed with CD4+ T-cell clones specific for defined epitopes of the bacterial proteins. We found that some epitopes are presented poorly or not at all when formaldehyde-treated proteins are used, whereas other epitopes are equally presented to T-cell clones when either formaldehyde-treated or untreated antigens are used. However, T-cell recognition could be restored by either antigen degradation before formaldehyde treatment or heat denaturation after such treatment. Parallel digestion with trypsin of both formaldehyde-treated and untreated proteins showed that fragments generated from the two forms of the same antigen were different in size. These results demonstrate that formaldehyde treatment can constrain antigen presentation to T cells and that this may be due to an altered proteolytic processing of formaldehyde-treated proteins.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7513307      PMCID: PMC186418          DOI: 10.1128/iai.62.5.1830-1834.1994

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  16 in total

1.  Diversity in MHC class II ovalbumin T cell epitopes generated by distinct proteases.

Authors:  L Vidard; K L Rock; B Benacerraf
Journal:  J Immunol       Date:  1992-07-15       Impact factor: 5.422

2.  Mutants of pertussis toxin suitable for vaccine development.

Authors:  M Pizza; A Covacci; A Bartoloni; M Perugini; L Nencioni; M T De Magistris; L Villa; D Nucci; R Manetti; M Bugnoli
Journal:  Science       Date:  1989-10-27       Impact factor: 47.728

3.  Genetic characterization of Bordetella pertussis filamentous haemagglutinin: a protein processed from an unusually large precursor.

Authors:  M Domenighini; D Relman; C Capiau; S Falkow; A Prugnola; V Scarlato; R Rappuoli
Journal:  Mol Microbiol       Date:  1990-05       Impact factor: 3.501

Review 4.  Antigen-presenting function of the macrophage.

Authors:  E R Unanue
Journal:  Annu Rev Immunol       Date:  1984       Impact factor: 28.527

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Development of a pertussis component vaccine in Japan.

Authors:  Y Sato; M Kimura; H Fukumi
Journal:  Lancet       Date:  1984-01-21       Impact factor: 79.321

7.  Properties of pertussis toxin mutant PT-9K/129G after formaldehyde treatment.

Authors:  L Nencioni; G Volpini; S Peppoloni; M Bugnoli; T De Magistris; I Marsili; R Rappuoli
Journal:  Infect Immun       Date:  1991-02       Impact factor: 3.441

8.  Human T cell clones define S1 subunit as the most immunogenic moiety of pertussis toxin and determine its epitope map.

Authors:  M T De Magistris; M Romano; A Bartoloni; R Rappuoli; A Tagliabue
Journal:  J Exp Med       Date:  1989-05-01       Impact factor: 14.307

9.  Dissecting human T cell responses against Bordetella species.

Authors:  M T De Magistris; M Romano; S Nuti; R Rappuoli; A Tagliabue
Journal:  J Exp Med       Date:  1988-10-01       Impact factor: 14.307

10.  Metabolic, humoral, and cellular responses in adult volunteers immunized with the genetically inactivated pertussis toxin mutant PT-9K/129G.

Authors:  A Podda; L Nencioni; M T De Magistris; A Di Tommaso; P Bossù; S Nuti; P Pileri; S Peppoloni; M Bugnoli; P Ruggiero
Journal:  J Exp Med       Date:  1990-09-01       Impact factor: 14.307

View more
  13 in total

1.  Long-term pertussis-specific immunity after primary vaccination with a combined diphtheria, tetanus, tricomponent acellular pertussis, and hepatitis B vaccine in comparison with that after natural infection.

Authors:  S Esposito; T Agliardi; A Giammanco; G Faldella; A Cascio; S Bosis; O Friscia; M Clerici; N Principi
Journal:  Infect Immun       Date:  2001-07       Impact factor: 3.441

2.  Host responses to recombinant hemagglutinin B of Porphyromonas gingivalis in an experimental rat model.

Authors:  J Katz; K P Black; S M Michalek
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

3.  Macrophages and enriched populations of T lymphocytes interact synergistically for the induction of severe, destructive Lyme arthritis.

Authors:  B K DuChateau; J R Jensen; D M England; S M Callister; S D Lovrich; R F Schell
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

4.  Mucosal vaccination with recombinantly attenuated staphylococcal enterotoxin B and protection in a murine model.

Authors:  B G Stiles; A R Garza; R G Ulrich; J W Boles
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

5.  Impact of Protein Glycosylation on the Design of Viral Vaccines.

Authors:  Kathleen Schön; Bernd Lepenies; Guillaume Goyette-Desjardins
Journal:  Adv Biochem Eng Biotechnol       Date:  2021       Impact factor: 2.635

Review 6.  Critical analysis of compositions and protective efficacies of oral killed cholera vaccines.

Authors:  Shahjahan Kabir
Journal:  Clin Vaccine Immunol       Date:  2014-07-23

7.  Cytokine mRNA expression and proliferative responses induced by pertussis toxin, filamentous hemagglutinin, and pertactin of Bordetella pertussis in the peripheral blood mononuclear cells of infected and immunized schoolchildren and adults.

Authors:  Q He; N N Tran Minh; K Edelman; M K Viljanen; H Arvilommi; J Mertsola
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

8.  Development of a subunit vaccine for prevention of Clostridium difficile associated diseases: Biophysical characterization of toxoids A and B.

Authors:  Alexey Gribenko; Elena Severina; Maninder K Sidhu; Kathrin U Jansen; Bruce A Green; Yury V Matsuka
Journal:  Biochem Biophys Rep       Date:  2017-01-05

9.  Glutaraldehyde Cross-linking of HIV-1 Env Trimers Skews the Antibody Subclass Response in Mice.

Authors:  Martina Soldemo; Monika Àdori; Julian M Stark; Yu Feng; Karen Tran; Richard Wilson; Lifei Yang; Javier Guenaga; Richard T Wyatt; Gunilla B Karlsson Hedestam
Journal:  Front Immunol       Date:  2017-11-27       Impact factor: 7.561

10.  Safety and immunogenicity of a combined Tetanus, Diphtheria, recombinant acellular Pertussis vaccine (TdaP) in healthy Thai adults.

Authors:  Chukiat Sirivichayakul; Pornthep Chanthavanich; Kriengsak Limkittikul; Claire-Anne Siegrist; Wassana Wijagkanalan; Pailinrut Chinwangso; Jean Petre; Pham Hong Thai; Mukesh Chauhan; Simonetta Viviani
Journal:  Hum Vaccin Immunother       Date:  2016-09-29       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.